Clinical Trials in Avellino, Italy
19 recruiting
Showing 1–20 of 26 trials
Recruiting
Phase 2Phase 3
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Non-small Cell Lung Cancer
BioNTech SE1,260 enrolled184 locationsNCT06712316
Recruiting
Phase 3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled383 locationsNCT05253651
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC380 enrolled45 locationsNCT07230691
Recruiting
Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Non-small Cell Lung CancerCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer714 enrolled315 locationsNCT06758401
Recruiting
Phase 3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled351 locationsNCT06065748
Recruiting
Phase 2Phase 3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Non-small Cell Lung Cancer
Bristol-Myers Squibb596 enrolled185 locationsNCT07100080
Recruiting
Phase 3
A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
HER2 MutationAdvanced Non-Small Cell Lung Cancer
Bayer278 enrolled283 locationsNCT06452277
Recruiting
Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy
Asthma
AstraZeneca300 enrolled30 locationsNCT06948396
Recruiting
Phase 3
Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer
Metastatic Colorectal Cancer (Mcrc)
University of Campania Luigi Vanvitelli480 enrolled41 locationsNCT07389265
Recruiting
Phase 1Phase 2
Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients
Relapsed or Refractory Hodgkin's Lymphoma
Fondazione Italiana Linfomi - ETS122 enrolled32 locationsNCT05300282
Recruiting
Phase 2
Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients
Follicular Lymphoma
Fondazione Italiana Linfomi - ETS56 enrolled24 locationsNCT06492837
Recruiting
Phase 2
A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
Diffuse Large B Cell Non-Hodgkin Lymphoma
Fondazione Italiana Linfomi - ETS47 enrolled20 locationsNCT06835530
Recruiting
A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice
Non-hodgkin Lymphoma,B Cell
Fondazione Italiana Linfomi - ETS1,500 enrolled61 locationsNCT06008691
Recruiting
Phase 3
Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi
Follicular Lymphoma
Fondazione Italiana Linfomi - ETS190 enrolled48 locationsNCT05929222
Recruiting
Phase 2
ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer
Colorectal Cancer Metastatic
National Cancer Institute, Naples130 enrolled8 locationsNCT06714357
Recruiting
SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project
Non-hodgkin Lymphoma,B Cell
Fondazione Italiana Linfomi - ETS130 enrolled21 locationsNCT06156774
Recruiting
Phase 2
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Metastatic Lung CancerAdvanced NSCLC
Mirati Therapeutics Inc.90 enrolled166 locationsNCT05609578
Recruiting
Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance
Follicular Lymphoma
Fondazione Italiana Linfomi - ETS56 enrolled14 locationsNCT06070961
Recruiting
Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma
Classical Hodgkin LymphomaClassical Hodgkin Lymphoma RecurrentClassical Hodgkin Lymphoma Refractory
Azienda USL Reggio Emilia - IRCCS755 enrolled12 locationsNCT06822855